About: Dabigatran versus Warfarin in Patients with Atrial Fibrillation

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Dabigatran versus Warfarin in Patients with Atrial Fibrillation Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
rdfs:seeAlso	http://dx.doi.org/10.1056/NEJMoa0905561
Description	Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin inhibitor. In this noninferiority trial, we randomly assigned 18,113 patients who had atrial fibrillation and a risk of stroke to receive, in a blinded fashion, fixed doses of dabigatran--110 mg or 150 mg twice daily--or, in an unblinded fashion, adjusted-dose warfarin. The median duration of the follow-up period was 2.0 years. The primary outcome was stroke or systemic embolism.RESULTS:Rates of the primary outcome were 1.69% per year in the warfarin group, as compared with 1.53% per year in the group that received 110 mg of dabigatran (relative risk with dabigatran, 0.91; 95% confidence interval [CI], 0.74 to 1.11; P<0.001 for noninferiority) and 1.11% per year in the group that received 150 mg of dabigatran (relative risk, 0.66; 95% CI, 0.53 to 0.82; P<0.001 for superiority). Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin inhibitor. In this noninferiority trial, we randomly assigned 18,113 patients who had atrial fibrillation and a risk of stroke to receive, in a blinded fashion, fixed doses of dabigatran--110 mg or 150 mg twice daily--or, in an unblinded fashion, adjusted-dose warfarin. The median duration of the follow-up period was 2.0 years. The primary outcome was stroke or systemic embolism.RESULTS:Rates of the primary outcome were 1.69% per year in the warfarin group, as compared with 1.53% per year in the group that received 110 mg of dabigatran (relative risk with dabigatran, 0.91; 95% confidence interval [CI], 0.74 to 1.11; P<0.001 for noninferiority) and 1.11% per year in the group that received 150 mg of dabigatran (relative risk, 0.66; 95% CI, 0.53 to 0.82; P<0.001 for superiority). (en)
Title	Dabigatran versus Warfarin in Patients with Atrial Fibrillation Dabigatran versus Warfarin in Patients with Atrial Fibrillation (en)
skos:prefLabel	Dabigatran versus Warfarin in Patients with Atrial Fibrillation Dabigatran versus Warfarin in Patients with Atrial Fibrillation (en)
skos:notation	RIV/00064203:_____/09:8871!RIV13-MZ0-00064203
http://linked.open...avai/riv/aktivita	I
http://linked.open...avai/riv/aktivity	I
http://linked.open...iv/cisloPeriodika	12
http://linked.open...vai/riv/dodaniDat	2013
http://linked.open...aciTvurceVysledku	Tomek, Aleš Šrámek, Martin
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Fakultní nemocnice v Motole
http://linked.open...dnocenehoVysledku	308963
http://linked.open...ai/riv/idVysledku	RIV/00064203:_____/09:8871
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	non-inferiority trial; antithrombotic therapy; anticoagulant-therapy; oral anticoagulant; prevent stroke; aspirin; thromboembolism; metaanalysis; clopidogrel; etexilate (en)
http://linked.open.../riv/klicoveSlovo	antithrombotic therapy prevent stroke non-inferiority trial anticoagulant-therapy etexilate clopidogrel metaanalysis thromboembolism aspirin oral anticoagulant
http://linked.open...odStatuVydavatele	US - Spojené státy americké
http://linked.open...ontrolniKodProRIV	[844319B6C006]
http://linked.open...i/riv/nazevZdroje	New England Journal of Medicine
http://linked.open...in/vavai/riv/obor	FA
http://linked.open...ichTvurcuVysledku	2 (xsd:int)
http://linked.open...cetTvurcuVysledku	1725 (xsd:int)
http://linked.open...UplatneniVysledku	2009
http://linked.open...v/svazekPeriodika	361
http://linked.open...iv/tvurceVysledku	Eikelboom, J. Tomek, Aleš Šrámek, Martin Alings, Marco Darius, Harald Eikelboom, John Oldgren, Jonas Pogue, Janice Wallentin, Lars Ezekowitz, Michael Diaz, Rafael Connolly, Stuart Diener, Hans-Christoph Joyner, Campbell Lewis, Basil Parekh, Amit Reilly, Paul Themeles, Ellison Varrone, Jeanne Wang, Susan Wulff, CW Xavier, Denis Yates, SW Yousuf, K. A. Yusuf, Salim Zakhary, GB Zambrano, R. Zhu, Jun Zimetbaum, P. Zoble, R. Zopo, AR Zwerner, PL
http://linked.open...ain/vavai/riv/wos	000269828000005
issn	0028-4793
number of pages	13 (xsd:int)
is http://linked.open...avai/riv/vysledek of	Dabigatran versus Warfarin in Patients with Atrial Fibrillation

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 58 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software